Next Article in Journal
Combined Cell Therapy in the Treatment of Neurological Disorders
Next Article in Special Issue
Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies
Previous Article in Journal
Genetic and Acquired Heterotopic Ossification: A Translational Tale of Mice and Men
Previous Article in Special Issue
8-Hydroxydaidzein, an Isoflavone from Fermented Soybean, Induces Autophagy, Apoptosis, Differentiation, and Degradation of Oncoprotein BCR-ABL in K562 Cells
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Anti-c-myc RNAi-Based Onconanotherapeutics

Nano-Gene and Drug Delivery Group, Discipline of Biochemistry, University of KwaZulu-Natal, Private Bag, Durban X54001, South Africa
*
Author to whom correspondence should be addressed.
Biomedicines 2020, 8(12), 612; https://doi.org/10.3390/biomedicines8120612
Submission received: 17 November 2020 / Revised: 3 December 2020 / Accepted: 5 December 2020 / Published: 15 December 2020

Abstract

Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly applicable and more effective form of cancer treatment than is currently available. The endogenous mechanism of RNA interference (RNAi), through which small RNA molecules induce gene silencing by binding to complementary mRNA transcripts, represents an attractive avenue for c-myc inhibition. However, the development of a clinically viable, anti-c-myc RNAi-based platform is largely dependent upon the design of an appropriate carrier of the effector nucleic acids. To date, organic and inorganic nanoparticles were assessed both in vitro and in vivo, as carriers of small interfering RNA (siRNA), DICER-substrate siRNA (DsiRNA), and short hairpin RNA (shRNA) expression plasmids, directed against the c-myc oncogene. We review here the various anti-c-myc RNAi-based nanosystems that have come to the fore, especially between 2005 and 2020.
Keywords: c-myc; RNA interference; siRNA; oncogene; gene silencing; expression; nanosystems c-myc; RNA interference; siRNA; oncogene; gene silencing; expression; nanosystems

Share and Cite

MDPI and ACS Style

Habib, S.; Ariatti, M.; Singh, M. Anti-c-myc RNAi-Based Onconanotherapeutics. Biomedicines 2020, 8, 612. https://doi.org/10.3390/biomedicines8120612

AMA Style

Habib S, Ariatti M, Singh M. Anti-c-myc RNAi-Based Onconanotherapeutics. Biomedicines. 2020; 8(12):612. https://doi.org/10.3390/biomedicines8120612

Chicago/Turabian Style

Habib, Saffiya, Mario Ariatti, and Moganavelli Singh. 2020. "Anti-c-myc RNAi-Based Onconanotherapeutics" Biomedicines 8, no. 12: 612. https://doi.org/10.3390/biomedicines8120612

APA Style

Habib, S., Ariatti, M., & Singh, M. (2020). Anti-c-myc RNAi-Based Onconanotherapeutics. Biomedicines, 8(12), 612. https://doi.org/10.3390/biomedicines8120612

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop